Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma
- PMID: 6201741
- DOI: 10.1056/NEJM198405313102204
Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma
Abstract
We detected des-gamma-carboxy prothrombin, an abnormal prothrombin, in the serum of 69 of 76 patients (91 per cent) with biopsy-confirmed hepatocellular carcinoma (the mean level of the abnormal prothrombin was 900 ng per milliliter). In contrast, levels of the abnormal prothrombin were low in patients with chronic active hepatitis (mean, 10 ng per milliliter) or metastatic carcinoma involving the liver (mean, 42 ng per milliliter), and undetectable in normal subjects. In five patients treated with vitamin K there was no reduction in abnormal prothrombin, indicating that its presence was not due to vitamin K deficiency. Surgical resection of tumors in two patients and chemotherapy in one patient markedly reduced abnormal-prothrombin concentrations, which later increased with recurrence of disease. Serum alpha-fetoprotein levels correlated poorly with abnormal-prothrombin levels. Together, the assay for abnormal prothrombin and the alpha-fetoprotein assay identified 64 of 76 patients with hepatoma (84 per cent). Abnormal prothrombin may be useful in the laboratory diagnosis of primary hepatocellular carcinoma.
Similar articles
-
Abnormal prothrombin (DES-gamma-carboxy prothrombin) in hepatocellular carcinoma.Hepatogastroenterology. 1991 Oct;38(5):450-3. Hepatogastroenterology. 1991. PMID: 1722483 Free PMC article.
-
Plasma abnormal prothrombin (des-gamma-carboxy prothrombin) as a marker of hepatocellular carcinoma.Cancer. 1988 Apr 15;61(8):1621-8. doi: 10.1002/1097-0142(19880415)61:8<1621::aid-cncr2820610820>3.0.co;2-c. Cancer. 1988. PMID: 2450634
-
Relationship between pathologic prognostic factors and abnormal levels of des-gamma-carboxy prothrombin and alpha-fetoprotein in hepatocellular carcinoma.Am J Surg. 1992 Feb;163(2):251-6. doi: 10.1016/0002-9610(92)90111-4. Am J Surg. 1992. PMID: 1371207
-
Diagnostic and prognostic value of alpha-fetoprotein, des-γ-carboxy prothrombin and squamous cell carcinoma antigen immunoglobulin M complexes in hepatocellular carcinoma.Minerva Med. 2011 Oct;102(5):363-71. Minerva Med. 2011. PMID: 22193346 Review.
-
Evaluation of the diagnostic accuracy of des-gamma-carboxy prothrombin and alpha-fetoprotein alone or in combination for hepatocellular carcinoma: A systematic review and meta-analysis.Surg Oncol. 2020 Sep;34:245-255. doi: 10.1016/j.suronc.2020.05.002. Epub 2020 May 21. Surg Oncol. 2020. PMID: 32891338 No abstract available.
Cited by
-
Prognosis of Patients with Hepatocellular Carcinoma Treated with TACE: A New Score Combining Alpha-Fetoprotein and Des-γ-Carboxy Prothrombin.J Hepatocell Carcinoma. 2024 Oct 22;11:1979-1992. doi: 10.2147/JHC.S481393. eCollection 2024. J Hepatocell Carcinoma. 2024. PMID: 39465043 Free PMC article.
-
Chinese expert consensus statement on the clinical application of AFP/AFP-L3%/DCP using GALAD and GALAD-like algorithm in HCC.J Clin Lab Anal. 2023 Dec;37(23-24):e24990. doi: 10.1002/jcla.24990. Epub 2023 Dec 8. J Clin Lab Anal. 2023. PMID: 38063322 Free PMC article.
-
Galad Score as a Prognostic Marker for Patients with Hepatocellular Carcinoma.Int J Mol Sci. 2023 Nov 18;24(22):16485. doi: 10.3390/ijms242216485. Int J Mol Sci. 2023. PMID: 38003675 Free PMC article.
-
Changes in the plasma abnormal prothrombin level following treatment of hepatocellular carcinoma.Cancer Chemother Pharmacol. 1992;31 Suppl:S146-9. doi: 10.1007/BF00687125. Cancer Chemother Pharmacol. 1992. PMID: 1281044
-
Establishment of an enzyme immunoassay using monoclonal antibody (HG1-219) and its application for the diagnosis of hepatocellular carcinoma.Jpn J Cancer Res. 1992 Dec;83(12):1366-72. doi: 10.1111/j.1349-7006.1992.tb02771.x. Jpn J Cancer Res. 1992. PMID: 1282911 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical